Variable | Total n = 184 |
---|---|
Gender, n (%) | |
Male | 81 (44.0) |
Female | 103 (56.0) |
Age at diagnosis, years | |
Mean (SD) | 60.5 (11.8) |
Median (IQR) | 63.2 (51.4–70.3) |
Tumor type, n (%) | |
Gastrointestinal | 70 (38.0) |
Breast | 47 (25.5) |
Lung | 29 (15.8) |
Urological/renal | 18 (9.8) |
Gynecologic | 9 (4.9) |
Other | 11 (6.0) |
Tumor stage, n (%) | |
Stage II | 15 (8.1) |
Stage III | 26 (14.1) |
Stage IV | 143 (77.7) |
Type of treatment, n (%) | |
Conventional chemotherapy | 81 (44.0) |
Targeted therapy | 103 (56.0) |
Previous lines of treatment, n | |
Mean (SD) | 1.44 (0.96) |
Median (IQR) | 1 (1–2) |
Treatment duration, months | |
Mean (SD) | 6.8 (6.8) |
Median (IQR) | 4 (2–8.5) |
Previous medical conditions | |
No | 58 (31.5) |
Yes | 126 (68.4) |
ECOG Performance Status | |
0 (Asymptomatic) | 9 (4.9) |
1 (Symptomatic, but completely ambulatory) | 142 (77.2) |
2 (Symptomatic, < 50% of time in bed) | 30 (16.3) |
3 (Symptomatic, > 50% of time in bed) | 3 (1.6) |